Analyst Graig Suvannavejh of Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), retaining the price target of $39.00. Graig Suvannavejh has given his Buy rating
Analyst Graig Suvannavejh of Mizuho Securities reiterated a Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report), retaining the price target of $39.00. Graig Suvannavejh has given his Buy rating
WATERTOWN, Mass., April 16, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the
EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
Tim Chiang, an analyst from Capital One Financial, maintained the Buy rating on EyePoint Pharmaceuticals (EYPT – Research Report). The associated price target remains the same with $50.00. Tim Chiang
מיזוהו מציעה שאנשים ירכשו מניות של EyePoint Pharmaceuticals משום שערכן של המניות ירד לאחרונה. הם מאוד בטוחים שהמניות שוות רכישה והציבו להן מחיר יעד של 39 דולר. לאחרונה, EyePoint Pharmaceuticals